Cetuximab, a human-mouse chimeric antibody directed against EGFR, has been registered for HNSCC, but it remains unclear whether its working mechanism relates to EGFR inhibition or activation of the immune system. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.